Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis

International Journal of Cancer

Volumn 121, Issue 2, 2007, Pages 329-338

  Frigerio, Simona ^a   Padberg, Barbara C ^a   Strebel, Räto T ^a   Lenggenhager, Daniela M ^a   Messthaler, Angelika ^a   Abdou, Marie Therese ^a   Moch, Holger ^a   Zimmermann, Dieter R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Bladder cancer; Cytology; FISH; Loss of heterozygosity (LOH); Microsatellite analysis

Indexed keywords

MICROSATELLITE DNA;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER CELL; CANCER CYTODIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; URINE CYTOLOGY;

AGED; DNA, NEOPLASM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 34250379557     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22690     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. 2002. CA Cancer J Clin 2005;55:74-108.
2. Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003;170: 438-41.
3. Fujii Y, Fukui I, Kihara K, Tsujii T, Kageyama Y, Oshima H. Late recurrence and progression after a long tumor-free period in primary Ta and bladder cancer. Eur Urol 1999;36:309-13.
4. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164:680-4.
5. Herring JC, Kamat AM. Treatment of muscle-invasive bladder cancer: progress and new challenges. Expert Rev Anticancer Ther 2004;4:1047-56.
6. O'Connor RC, Alsikati NF, Steinberg GD. Therapeutic options and treatment of muscle invasive bladder cancer. Expert Rev Anticancer Ther 2001;1:511-22.
7. Herr HW, Donal SM, Dalbagni G. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002;168: 978-80.
8. Curry JL, Wojcik EM. The effects of the current World Health Organization/International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results. Cancer 2002;96:140-5.
9. Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol 1985;29:810-16.
10. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 2006;24:326-37.
11. Obermann EC, Junker K, Stoehr R, Dietmaier W, Zaak D, Schubert J, Hofstaedter F, Knuechel R, Hartmann A. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH and FISH analyses. J Pathol 2003;199: 50-7.
12. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; 47:736-48.
13. Orlow I, Lianas P, Lacombe L, Dalbagni G, Reuter VE, Cordon-Cardo C. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res 1994;54:2848-51.
14. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-25.
15. Presti JC, Jr. Reuter VE, Galan T, Fair WR, Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 1991;51:5405-9.
16. Choi C, Kim MH, Juhng SW, Oh BR. Loss of heterozygosity at chromosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of the urinary bladder. Int J Cancer 2000;86:501-5.
17. Stoehr R, Wissniann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004;84: 465-78.
18. Fearon ER, Feinberg AP, Hamilton SH, Vogelstein B. Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 1985;318:377-80.
19. Wada T, Louhelainen J, Hemminki K, Adolfsson J, Wijkstrom H, Norming U, Borgstrom E, Hansson J, Sandstedt B, Steineck G. Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade. Clin Cancer Res 2000;6:610-15.
20. Yoon DS, Li L, Zhang RD, Kram A, Ro JY, Johnston D, Grossman HB, Seherer S, Czerniak B. Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease. Oncogene 2001;20:5005-14.
21. Olumi AF, Tsai YC, Nichols PW, Skinner DG, Cain DR, Bender LI, Jones PA. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990;50:7081-3.
22. Eissa S, Kassim S, Et-Ahmady O. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol 2003;15:395-403.
23. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116: 79-86.
24. Degtyar P, Neulander E, Zirkin H, Yusim I, Douvdevani A, Mermershtain W, Kaneti J, Manor E. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Urology 2004;63:398-401.
25. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002;42:547-52.
26. Mao L, Sehoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, Sidransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271:659-62.
27. Linn JF, Lango M, Hatachmi S, Schoenberg MP, Sidransky D. Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer 1997;74:625-9.
28. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997;3:621-4.
29. Sobin L, Wittekind C. TNM classification of malignant tumors,6th edn. Baltimore, MD: Wiley-Lyss. 2002.
30. Eble J, Sauter G, Epstein J, Sesterhenn I. Tumors of the urinary system and male genital organsed. Lyon: IARC Press. 2004.
31. van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, Zwarthoff EC. The random development of LOH on chromosome 9q in superficial bladder cancers. J Pathol 2002;198:352-8.
32. Knowles MA. Identification of novel bladder tumour suppressor genes. Electrophoresis 1999;20:269-79.
33. Hyun JS, Jo BK, Park CJ, Yi JY, Lee JY, Rhyu MG. Loss of heterozygosity and PCR artifacts in a microsatellite analysis of psoriasis and colorectal cancer. J Korean Med Sci 2002;17:641-7.
34. Sieben NL, ter Haar NT, Cornelisse CJ, Fleuren GJ, Cleton-Jansen AM. PCR artifacts in LOH and MSI analysis of microdissected tumor cells. Hum Pathol 2000;31:1414-19.
35. Fornari D, Steven K, Hansen AB, Vibits H, Jepsen JV, Poulsen AL, Schwartz M, Horn T. Under-representation of bladder transitional cell tumour 9q. 11p and 14q LOH in urine and impact on molecular diagnosis. Anticancer Res 2005;25:4049-52.
36. Simon R, Jones PA, Sidransky D, Cordon-Cardo C, Cairns P. Amin MB, Gasser T, Knowles MA. Genetics and predictive factors of non-invasive urothelial neoplasiased. Lyon: IARC Press, 2004.
37. Little B. Non-invasive methods of bladder cancer detection. Int Urol Nephrol 2003;35:331-43.